15 results
Search Results
Now showing 1 - 10 of 15
Publication Metadata only Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial(2020-04-25) Rob W. van der Pluijm; Rupam Tripura; Richard M. Hoglund; Aung Pyae Phyo; Dysoley Lek; Akhter ul Islam; Anupkumar R. Anvikar; Parthasarathi Satpathi; Sanghamitra Satpathi; Prativa Kumari Behera; Amar Tripura; Subrata Baidya; Marie Onyamboko; Nguyen Hoang Chau; Yok Sovann; Seila Suon; Sokunthea Sreng; Sivanna Mao; Savuth Oun; Sovannary Yen; Chanaki Amaratunga; Kitipumi Chutasmit; Chalermpon Saelow; Ratchadaporn Runcharern; Weerayuth Kaewmok; Nhu Thi Hoa; Ngo Viet Thanh; Borimas Hanboonkunupakarn; James J. Callery; Akshaya Kumar Mohanty; James Heaton; Myo Thant; Kripasindhu Gantait; Tarapada Ghosh; Roberto Amato; Richard D. Pearson; Christopher G. Jacob; Sónia Gonçalves; Mavuto Mukaka; Naomi Waithira; Charles J. Woodrow; Martin P. Grobusch; Michele van Vugt; Rick M. Fairhurst; Phaik Yeong Cheah; Thomas J. Peto; Lorenz von Seidlein; Mehul Dhorda; Richard J. Maude; Markus Winterberg; Nguyen Thanh Thuy-Nhien; Dominic P. Kwiatkowski; Mallika Imwong; Podjanee Jittamala; Khin Lin; Tin Maung Hlaing; Kesinee Chotivanich; Rekol Huy; Caterina Fanello; Elizabeth Ashley; Mayfong Mayxay; Paul N. Newton; Tran Tinh Hien; Neena Valecha; Frank Smithuis; Sasithon Pukrittayakamee; Abul Faiz; Olivo Miotto; Joel Tarning; Nicholas P.J. Day; Nicholas J. White; Arjen M. Dondorp; Aung Pyae Phyo; Neena Valeche; Nicholas PJ Day; Oxford University Clinical Research Unit; Ispat General Hospital; Harvard T.H. Chan School of Public Health; University of Oxford; National Institute of Malaria Research India; National Institute of Allergy and Infectious Diseases; Mahosot Hospital, Lao; Mahidol University; Open University; Nuffield Department of Clinical Medicine; Wellcome Sanger Institute; AstraZeneca; Universiteit van Amsterdam; National Institute of Public Health; Pailin Provincial Health Department; Myanmar Oxford Clinical Research Unit; Kinshasa Mahidol Oxford Research Unit (KIMORU); Asia Regional Centre; Ramu Upazila Health Complex; Malaria Research Group and Dev Care Foundation; Defence Services Medical Academy; Khun Han Hospital; Phusing Hospital; Ratanakiri Referral Hospital; Sampov Meas Referral Hospital; Agartala Medical College; Royal Society of Thailand; Midnapore Medical College; National Centre for Parasitology, Entomology and Malaria Control; Kinshasa School of Public Health; University of Health Sciences; IGHor mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia..., Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plusPublication Metadata only Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial(2021-10-01) Mainga Hamaluba; Rob W. van der Pluijm; Joseph Weya; Patricia Njuguna; Mwanajuma Ngama; Peter Kalume; Gabriel Mwambingu; Caroline Ngetsa; Juliana Wambua; Mwanamvua Boga; Neema Mturi; Altaf A. Lal; Arshad Khuroo; Walter R.J. Taylor; Sónia Gonçalves; Olivo Miotto; Mehul Dhorda; Brian Mutinda; Mavuto Mukaka; Naomi Waithira; Richard M. Hoglund; Mallika Imwong; Joel Tarning; Nicholas P.J. Day; Nicholas J. White; Philip Bejon; Arjen M. Dondorp; Faculty of Tropical Medicine, Mahidol University; Wellcome Trust Research Laboratories Nairobi; Nuffield Department of Medicine; Wellcome Sanger Institute; Sun Pharmaceutical Industries Ltd.; Worldwide Antimalarial Resistance Networkor contraindication to any of the study drugs, and a QT interval corrected for heart rate (QTc interval) longer than 450 ms. Patients were randomly assigned (1:1:1), by use of blocks of six, nine, and 12, and opaque, sealed, and sequentially numbered envelopes... treatments was −7%. The study is registered in ClinicalTrials.gov, NCT03452475, and is completed. Findings: Between March 7, 2018, and May 2, 2019, 533 children with P falciparum were screened, of whom 217 were randomly assigned to receive either arterolanePublication Metadata only Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos(2014-07-15) Mayfong Mayxay; Maniphone Khanthavong; Lorna Cox; Odai Sichanthongthip; Mallika Imwong; Tiengkham Pongvongsa; Bouasy Hongvanthong; Samlane Phompida; Viengxay Vanisaveth; Nicholas J. White; Paul N. Newton; Mahosot Hospital; University of Health Sciences; University of Oxford; Centre of Malariology; MRC Human Nutrition Research; Mahidol University; Savannakhet Provincial Malaria Stationmalaria was conducted in Xepon District, Savannakhet Province, southern Laos. Patients were randomly assigned to either oral thiamin 10 mg/day for 7 days immediately after standard anti-malarial treatment then 5 mg daily until day 42, or identical oralPublication Open Access Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay.(2011) Campino, Susana; Auburn, Sarah; Kivinen, Katja; Zongo, Issaka; Ouedraogo, Jean-Bosco; Mangano, Valentina; Djimde, Abdoulaye; Doumbo, Ogobara K.; Kiara, Steven M.; Nzila, Alexis; Borrmann, Steffen; Marsh, Kevin; Michon, Pascal; Mueller, Ivo; Siba, Peter; Jiang, Hongying; Su, Xin-Zhuan; Chanaki Amaratunga; Socheat, Duong; Fairhurst, Rick M.; Mallika Imwong; มัลลิกา อิ่มวงศ์; Anderson, Timothy; Nosten, Francois; White, Nicholas J.; Gwilliam, Rhian; Deloukas, Panos; MacInnis, Bronwyn; Newbold, Christopher I.; Rockett, Kirk; Clark, Taane G.; Kwiatkowski, Dominic P.; Campino, Susana; Fitzgerald, J. Ross; Mahidol University. Faculty of Tropical Medicine. Mahidol-Oxford University Research Unit.; Mahidol University. Faculty of Tropical Medicine. Department of Clinical Tropical Medicine.; Mahidol University. Faculty of Tropical Medicine. Department of Molecular Tropical Medicine and Genetics.The diversity in the Plasmodium falciparum genome can be used to explore parasite population dynamics, with practical applications to malaria control. The ability to identify the geographic origin and trace the migratory patterns of parasites with clinically important phenotypes such as drug resistance is particularly relevant. With increasing single-nucleotide polymorphism (SNP) discovery from ongoing Plasmodium genome sequencing projects, a demand for high SNP and sample throughput genotyping platforms for large-scale population genetic studies is required. Low parasitaemias and multiple clone infections present a number of challenges to genotyping P. falciparum. We addressed some of these issues using a custom 384-SNP Illumina GoldenGate assay on P. falciparum DNA from laboratory clones (long-term cultured adapted parasite clones), short-term cultured parasite isolates and clinical (non-cultured isolates) samples from East and West Africa, Southeast Asia and Oceania. Eighty percent of the SNPs (n = 306) produced reliable genotype calls on samples containing as little as 2 ng of total genomic DNA and on whole genome amplified DNA. Analysis of artificial mixtures of laboratory clones demonstrated high genotype calling specificity and moderate sensitivity to call minor frequency alleles. Clear resolution of geographically distinct populations was demonstrated using Principal Components Analysis (PCA), and global patterns of population genetic diversity were consistent with previous reports. These results validate the utility of the platform in performing population genetic studies of P. falciparum.Publication Metadata only Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: An open-label randomised trial(2010-10-01) Frank Smithuis; Moe Kyaw Kyaw; Ohn Phe; Thein Win; Pyay Phyo Aung; Aung Pyay Phyo Oo; Arkar Linn Naing; Mya Yee Nyo; Naing Zaw Htun Myint; Mallika Imwong; Elizabeth Ashley; Sue J. Lee; Nicholas J. White; Médecins sans Frontières-Holland; Mahidol University; Churchill Hospitalmonths, and who weighed more than 5 kg. Treatments were randomised in equal numbers within blocks of 50 and allocation was in sealed envelopes. All patients were also randomly assigned to receive either a single dose of primaquine 0·75 mg base/kgPublication Metadata only Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials(2020-01-01) Koukeo Phommasone; Frank van Leth; Thomas J. Peto; Jordi Landier; Thuy Nhien Nguyen; Rupam Tripura; Tiengkham Pongvongsa; Khin Maung Lwin; Ladda Kajeechiwa; May Myo Thwin; Daniel M. Parker; Jacher Wiladphaingern; Suphak Nosten; Stephane Proux; Chea Nguon; Chan Davoeung; Huy Rekol; Bipin Adhikari; Cholrawee Promnarate; Kesinee Chotivanich; Borimas Hanboonkunupakarn; Podjanee Jittmala; Phaik Yeong Cheah; Mehul Dhorda; Mallika Imwong; Mavuto Mukaka; Pimnara Peerawaranun; Sasithon Pukrittayakamee; Paul N. Newton; Guy E. Thwaites; Nicholas P.J. Day; Mayfong Mayxay; Tran Tinh Hien; Francois H. Nosten; Frank Cobelens; Arjen M. Dondorp; Nicholas J. White; Lorenz von Seidlein; Aix Marseille Université; Mahidol University; Nuffield Department of Clinical Medicine; University of California, Irvine; Amsterdam UMC - University of Amsterdam; Oxford University Clinical Research Unit; University of Health Sciences; Amsterdam Institute for Global Health and Development; Mahosot Hospital; Savannakhet Provincial Health Department; Royal Institute of Thailand; National Center for Parasitology, Entomology and Malaria Control; Provincial Health Department. Methods Between May 2013 and July 2017, four villages in each Myanmar, Vietnam, Cambodia and Lao PDR were selected based on high prevalence of P. falciparum infections. Eight of the 16 villages were randomly assigned to receive MDA consisting of threePublication Metadata only Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study(2019-09-01) Rob W. van der Pluijm; Mallika Imwong; Nguyen Hoang Chau; Nhu Thi Hoa; Nguyen Thanh Thuy-Nhien; Ngo Viet Thanh; Podjanee Jittamala; Borimas Hanboonkunupakarn; Kitipumi Chutasmit; Chalermpon Saelow; Ratchadaporn Runjarern; Weerayuth Kaewmok; Rupam Tripura; Thomas J. Peto; Sovann Yok; Seila Suon; Sokunthea Sreng; Sivanna Mao; Savuth Oun; Sovannary Yen; Chanaki Amaratunga; Dysoley Lek; Rekol Huy; Mehul Dhorda; Kesinee Chotivanich; Elizabeth A. Ashley; Mavuto Mukaka; Naomi Waithira; Phaik Yeong Cheah; Richard J. Maude; Roberto Amato; Richard D. Pearson; Sónia Gonçalves; Christopher G. Jacob; William L. Hamilton; Rick M. Fairhurst; Joel Tarning; Markus Winterberg; Dominic P. Kwiatkowski; Sasithon Pukrittayakamee; Tran Tinh Hien; Nicholas PJ Day; Olivo Miotto; Nicholas J. White; Arjen M. Dondorp; Harvard T.H. Chan School of Public Health; University of Oxford; UCL; National Institute of Allergy and Infectious Diseases; Mahidol University; Nuffield Department of Clinical Medicine; Wellcome Sanger Institute; Pailin Provincial Health Department; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU); Khun Han Hospital; Phusing Hospital; World Wide Antimalarial Resistance Network (WWARN)-Asia Regional Centre; Ratanakiri Referral Hospital; Sampov Meas Referral Hospital; Royal Institute of Thailand; National Institute of Public Health; National Center for Parasitology, Entomology and Malaria Controlin Thailand, Cambodia, and Vietnam were randomly assigned to receive dihydroartemisinin-piperaquine with or without mefloquine, as part of the TRACII trial. The primary outcome was the PCR-corrected efficacy at day 42. Next-generation sequencing was usedPublication Open Access Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1.(2005-04-27) Mallika Imwong; มัลลิกา อิ่มวงศ์; Sasithon Pukrittayakamee; Grüner, Anne Charlotte; Rénia, Laurent; Letourneur, Frank; Sornchai Looareesuwan; ศรชัย หลูอารีย์สุวรรณ; White, Nicholas J.; Snounou, Georges; Mallika Imwong; Mahidol University. Faculty of Tropical Medicine. Department of Clinical Tropical Medicine.patients with slide confirmed uncomplicated P. falciparum malaria were randomly assigned to receive artemether-lumefantrine (n = 245) or artesunate and mefloquine (n = 245) and were followed for 42 days. All patients had rapid initial clinicalPublication Open Access Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos(2014-07-15) Mayxay, Mayfong; Khanthavong, Maniphone; Cox, Lorna; Sichanthongthip, Odai; Mallika Imwong; มัลลิกา อิ่มวงศ์; Pongvongsa, Tiengkham; Hongvanthong, Bouasy; Phompida, Samlane; Vanisaveth, Viengxay; White, Nicholas J; Newton, Paul N; Mayxay, Mayfong; Mahidol University. Faculty of Tropical Medicine. Department of Molecular Tropical Medicine and Genetics.malaria was conducted in Xepon District, Savannakhet Province, southern Laos. Patients were randomly assigned to either oral thiamin 10 mg/day for 7 days immediately after standard anti-malarial treatment then 5 mg daily until day 42, or identical oralPublication Open Access Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border(2010-11-01) Takeuchi, Rie; Saranath Lawpoolsri; สารนาถ ล้อพูลศรี; Mallika Imwong; มัลลิกา อิ่มวงศ์; Kobayashi, Jun; Jaranit Kaewkungwal; จรณิต แก้วกังวาล; Sasithon Pukrittayakamee; ศศิธร ผู้กฤตยาคามี; Supalap Puangsa-art; ศุภลาภ พวงสอาด; Nipon Thanyavanich; นิพนธ์ ธัญญวานิช; Wanchai Maneeboonyang; วรรณไชย มณีบุญยัง; Day, Nicholas P.J.; Pratap Singhasivanon; ประตาป สิงหศิวานนท์; Pratap Singhasivanon; Mahidol University. Faculty of Tropical Medicine. Department of Clinical Tropical Medicine; Mahidol University. Faculty of Tropical Medicine. Mahidol-Oxford Tropical Medicine Research Unit (MORU); Mahidol University. Faculty of Tropical Medicine. Department of Tropical Hygiene.BACKGROUND: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the drug and adherence to the 14-day regimen. This study examined the effectiveness of using the directly-observed therapy (DOT) method for the radical treatment of P. vivax malaria infection, to prevent reappearance of the parasite within the 90-day follow-up period. Other potential risk factors for the reappearance of P. vivax were also explored. METHODS: A randomized trial was conducted from May 2007 to January 2009 in a low malaria transmission area along the Thai-Myanmar border. Patients aged ≥ 3 years diagnosed with P. vivax by microscopy, were recruited. All patients were treated with the national standard regimen of chloroquine for three days followed by primaquine for 14 days. Patients were randomized to receive DOT or self-administered therapy (SAT). All patients were followed for three months to check for any reappearance of P. vivax. RESULTS: Of the 216 patients enrolled, 109 were randomized to DOT and 107 to SAT. All patients recovered without serious adverse effects. The vivax reappearance rate was significantly lower in the DOT group than the SAT group (3.4/10,000 person-days vs. 13.5/10,000 person-days, p = 0.021). Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2.75 mg/kg), duration of fever ≤ 2 days before initiation of treatment, parasite count on admission ≥ 10,000/µl, multiple P. vivax-genotype infection, and presence of P. falciparum infection during the follow-up period. CONCLUSIONS: Adherence to the 14-day primaquine regimen is important for the radical cure of P. vivax malaria infection. Implementation of DOT reduces the reappearance rate of the parasite, and may subsequently decrease P. vivax transmission in the area.